Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

MSD has joined fellow big pharmas in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027.

Fiction has been preparing us for an unseen, all knowing CEO for decades. Now technology could make it reality.

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

Multiple myeloma pathogenesis is marked by incredibly complex processes that range beyond primary or acquired genetic alterations, with factors in the ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after second-quarter sales ...

Indonesia is ready to lead the region in future pandemic responses, but without stronger global support, its vaccine ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted th ...

Jim Cramer threw a curveball on Pfizer’s stock during a recent caller interaction, suggesting a wait-and-see approach ...